Charles Schwab Investment Management Inc Phathom Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 360,160 shares of PHAT stock, worth $4.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
360,160
Previous 348,035
3.48%
Holding current value
$4.3 Million
Previous $2.18 Million
58.25%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding PHAT
# of Institutions
137Shares Held
60.5MCall Options Held
1.35MPut Options Held
1.19M-
Frazier Life Sciences Management, L.P. Menlo Park, CA12.5MShares$149 Million6.31% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$89.1 Million20.28% of portfolio
-
Invesco Ltd. Atlanta, GA4.14MShares$49.4 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$41.8 Million41.56% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$34.9 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $468M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...